Boston Scientific Corp. (NYSE:BSX)’s share price hit a new 52-week high on Wednesday . The company traded as high as $24.45 and last traded at $24.30, with a volume of 6,621,862 shares changing hands. The stock had previously closed at $23.75.

BSX has been the topic of a number of research reports. Bank of America Corp. reissued a “buy” rating and set a $23.00 price objective on shares of Boston Scientific Corp. in a report on Friday, March 25th. Morgan Stanley reissued an “overweight” rating and set a $22.00 price objective on shares of Boston Scientific Corp. in a report on Sunday, March 27th. Stifel Nicolaus reissued a “buy” rating and set a $22.00 price objective on shares of Boston Scientific Corp. in a report on Wednesday, April 6th. Goldman Sachs Group Inc. raised their price objective on Boston Scientific Corp. from $21.00 to $22.00 in a report on Friday, April 8th. Finally, Argus reissued a “hold” rating on shares of Boston Scientific Corp. in a report on Sunday, April 10th. Four investment analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $23.49.

The firm’s market cap is $32.46 billion. The stock’s 50-day moving average price is $23.16 and its 200 day moving average price is $20.06.

Boston Scientific Corp. (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 27th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.04. The business earned $1.96 billion during the quarter, compared to analysts’ expectations of $1.91 billion. During the same quarter in the previous year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. On average, analysts predict that Boston Scientific Corp. will post $1.09 EPS for the current year.

In other news, SVP David A. Pierce sold 2,480 shares of the stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $24.03, for a total value of $59,594.40. Following the sale, the senior vice president now directly owns 28,080 shares in the company, valued at $674,762.40. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP John Bradley Sorenson sold 2,800 shares of the stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $22.15, for a total value of $62,020.00. Following the completion of the sale, the senior vice president now owns 15,115 shares in the company, valued at $334,797.25. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Standard Life Investments LTD increased its position in Boston Scientific Corp. by 4.7% in the fourth quarter. Standard Life Investments LTD now owns 20,081,140 shares of the company’s stock valued at $370,397,000 after buying an additional 902,531 shares during the last quarter. Systematic Financial Management LP increased its position in Boston Scientific Corp. by 4.8% in the fourth quarter. Systematic Financial Management LP now owns 3,659,104 shares of the company’s stock valued at $67,473,000 after buying an additional 167,539 shares during the last quarter. Wells Fargo & Company MN increased its position in Boston Scientific Corp. by 8.5% in the fourth quarter. Wells Fargo & Company MN now owns 3,302,731 shares of the company’s stock valued at $60,902,000 after buying an additional 260,006 shares during the last quarter. Mizuho Trust & Banking Co. Ltd. increased its position in Boston Scientific Corp. by 3.4% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 2,080,627 shares of the company’s stock valued at $38,720,000 after buying an additional 67,512 shares during the last quarter. Finally, Morgan Stanley increased its position in Boston Scientific Corp. by 11.3% in the fourth quarter. Morgan Stanley now owns 1,919,754 shares of the company’s stock valued at $35,401,000 after buying an additional 194,734 shares during the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.